Cerevel Therapeutics Holdings Inc
NASDAQ:CERE
Income Statement
Earnings Waterfall
Cerevel Therapeutics Holdings Inc
Revenue
|
0
USD
|
Cost of Revenue
|
-77m
USD
|
Gross Profit
|
-77m
USD
|
Operating Expenses
|
-370.3m
USD
|
Operating Income
|
-447.3m
USD
|
Other Expenses
|
14.4m
USD
|
Net Income
|
-432.8m
USD
|
Income Statement
Cerevel Therapeutics Holdings Inc
Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Gross Profit | ||||||||||||||
Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(61)
|
0
|
0
|
0
|
(77)
|
|
Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
(61)
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
(77)
N/A
|
|
Operating Income | ||||||||||||||
Operating Expenses |
(149)
|
(200)
|
(250)
|
(302)
|
(220)
|
(242)
|
(285)
|
(325)
|
(307)
|
(395)
|
(399)
|
(415)
|
(370)
|
|
Selling, General & Administrative |
(46)
|
(60)
|
(73)
|
(84)
|
(58)
|
(62)
|
(69)
|
(78)
|
(88)
|
(91)
|
(94)
|
(96)
|
(113)
|
|
Research & Development |
(103)
|
(140)
|
(177)
|
(217)
|
(162)
|
(180)
|
(216)
|
(247)
|
(219)
|
(303)
|
(305)
|
(319)
|
(258)
|
|
Operating Income |
(149)
N/A
|
(200)
-34%
|
(250)
-25%
|
(302)
-21%
|
(220)
+27%
|
(242)
-10%
|
(285)
-18%
|
(325)
-14%
|
(368)
-13%
|
(395)
-7%
|
(399)
-1%
|
(415)
-4%
|
(447)
-8%
|
|
Pre-Tax Income | ||||||||||||||
Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
1
|
13
|
6
|
2
|
18
|
15
|
|
Total Other Income |
(3)
|
(4)
|
(6)
|
(14)
|
(5)
|
(1)
|
3
|
6
|
3
|
1
|
1
|
4
|
(0)
|
|
Pre-Tax Income |
(152)
N/A
|
(203)
-33%
|
(256)
-26%
|
(315)
-23%
|
(225)
+29%
|
(243)
-8%
|
(280)
-15%
|
(318)
-14%
|
(351)
-11%
|
(387)
-10%
|
(396)
-2%
|
(393)
+1%
|
(432)
-10%
|
|
Net Income | ||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
|
Income from Continuing Operations |
(152)
|
(203)
|
(256)
|
(315)
|
(225)
|
(243)
|
(280)
|
(318)
|
(352)
|
(388)
|
(397)
|
(393)
|
(433)
|
|
Net Income (Common) |
(148)
N/A
|
(199)
-34%
|
(252)
-27%
|
(311)
-23%
|
(225)
+28%
|
(243)
-8%
|
(280)
-15%
|
(318)
-14%
|
(352)
-11%
|
(388)
-10%
|
(397)
-2%
|
(393)
+1%
|
(433)
-10%
|
|
EPS (Diluted) |
-2.01
N/A
|
-1.56
+22%
|
-1.97
-26%
|
-2.16
-10%
|
-1.65
+24%
|
-1.63
+1%
|
-1.9
-17%
|
-2.08
-9%
|
-2.32
-12%
|
-2.47
-6%
|
-2.52
-2%
|
-2.5
+1%
|
-2.67
-7%
|